CA3010848A1 - Combination of a chromene compound and a second active agent - Google Patents

Combination of a chromene compound and a second active agent Download PDF

Info

Publication number
CA3010848A1
CA3010848A1 CA3010848A CA3010848A CA3010848A1 CA 3010848 A1 CA3010848 A1 CA 3010848A1 CA 3010848 A CA3010848 A CA 3010848A CA 3010848 A CA3010848 A CA 3010848A CA 3010848 A1 CA3010848 A1 CA 3010848A1
Authority
CA
Canada
Prior art keywords
group
compound
chromene
trifluoromethyl
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3010848A
Other languages
English (en)
French (fr)
Inventor
John J. Talley
Bobby W. SANDAGE
Eduardo J. Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euclises Pharmaceuticals Inc
Original Assignee
Euclises Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euclises Pharmaceuticals Inc filed Critical Euclises Pharmaceuticals Inc
Publication of CA3010848A1 publication Critical patent/CA3010848A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3010848A 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent Pending CA3010848A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (1)

Publication Number Publication Date
CA3010848A1 true CA3010848A1 (en) 2017-07-13

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010848A Pending CA3010848A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Country Status (9)

Country Link
US (2) US20170196835A1 (enExample)
EP (1) EP3400218A4 (enExample)
JP (1) JP6942726B2 (enExample)
KR (1) KR20180100652A (enExample)
CN (1) CN108779091B (enExample)
AU (1) AU2017206108B2 (enExample)
CA (1) CA3010848A1 (enExample)
MX (1) MX388579B (enExample)
WO (1) WO2017120591A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
EP3656400A4 (en) * 2017-07-20 2021-10-20 National University Corporation Hokkaido University USE IN COMBINATION OF A TARGETING PD-1 / PD-L1 INHIBITOR AND A COX-2 INHIBITOR
NZ749727A (en) 2018-01-05 2020-07-31 Gnt Biotech & Medicals Corp A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
WO2021084441A2 (en) * 2019-10-28 2021-05-06 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer
CA3159783A1 (en) 2019-11-12 2021-05-20 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in treating of cancer and methods thereof
KR102797536B1 (ko) 2020-04-29 2025-04-22 릴레이 테라퓨틱스, 인크. PI3Kα 억제제 및 이의 사용 방법
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
KR102889598B1 (ko) * 2023-02-16 2025-11-21 주식회사 재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20120016002A1 (en) 2007-07-12 2012-01-19 TRAGARA PHARMACEUTICALS ,Inc. Patient Selection and Therapeutic Methods Using Markers of Prostaglandin Metabolism
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CN107252485A (zh) * 2013-04-03 2017-10-17 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Also Published As

Publication number Publication date
EP3400218A1 (en) 2018-11-14
CN108779091B (zh) 2022-12-27
JP2019501224A (ja) 2019-01-17
WO2017120591A1 (en) 2017-07-13
MX388579B (es) 2025-03-20
CN108779091A (zh) 2018-11-09
EP3400218A4 (en) 2019-09-18
US20170196835A1 (en) 2017-07-13
AU2017206108A1 (en) 2018-08-02
US20220265602A1 (en) 2022-08-25
AU2017206108B2 (en) 2021-10-28
KR20180100652A (ko) 2018-09-11
MX2018008433A (es) 2019-03-28
JP6942726B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
US20220265602A1 (en) Combination of a chromene compound and a second active agent
JP2020169223A (ja) 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
CN114466839A (zh) Tead抑制剂和其用途
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
US20180125817A1 (en) Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
JP7386842B2 (ja) ナフチリジン化合物およびその使用
US20160303249A1 (en) Combination of aurora kinase inhibitors and anti-cd30 antibodies
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
JP2024514836A (ja) Ｃｂｌ－ｂ阻害化合物との組み合わせ療法
JP2021121629A (ja) Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
WO2017201043A1 (en) Combination therapy for treating cancer
WO2023053142A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
HK40000167A (en) Combination of a chromene compound and a second active agent
HK40000167B (en) Combination of a chromene compound and a second active agent
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229

EEER Examination request

Effective date: 20211229